Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial
In this narrative review, data about how to reduce residual risk through the best antithrombotic
approach among patients with peripheral artery disease, with a particular focus
on the COMPASS trial, are updated in order to provide some
practical recommendations about its use in this population.